Humanization and characterization of the anti-HLA-DR antibody 1D10.
about
A humanized HLA-DR antibody (hu1D10, apolizumab) in combination with granulocyte colony-stimulating factor (filgrastim) for the treatment of non-Hodgkin's lymphoma: a pilot studyEmerging drugs for chronic lymphocytic leukaemia.Antibody therapy for chronic lymphocytic leukemia.Monoclonal antibody therapy of B cell lymphoma.Characterization of a humanized IgG4 anti-HLA-DR monoclonal antibody that lacks effector cell functions but retains direct antilymphoma activity and increases the potency of rituximabTargeted therapy for hematologic malignancies.Targeting T cells with bispecific antibodies for cancer therapyInvestigational immunotherapeutics for B-cell malignancies.New antibody drug treatments for lymphoma.Development and prospects for bispecific antibody-based therapeutics in cancer and other applications.A bispecific antibody directly induces lymphoma cell death by simultaneously targeting CD20 and HLA-DR.Combination immunotherapy with anti-CD20 and anti-HLA-DR monoclonal antibodies induces synergistic anti-lymphoma effects in human lymphoma cell lines.Fully human antibody exhibits pan-human leukocyte antigen-DR recognition and high in vitro/vivo efficacy against human leukocyte antigen-DR-positive lymphomas.Apoptosis assays with lymphoma cell lines: problems and pitfalls.Targeting HLA-DR.A phase I/II dose escalation study of apolizumab (Hu1D10) using a stepped-up dosing schedule in patients with chronic lymphocytic leukemia and acute leukemia.Characterization of humanized antibodies secreted by Aspergillus niger.Mitochondria control of cell death induced by anti-HLA-DR antibodies.The histone deacetylase inhibitor MS-275 induces caspase-dependent apoptosis in B-cell chronic lymphocytic leukemia cells.In Vivo Pharmacodynamic Effects of Hu1D10 (Remitogen), a Humanized Antibody Reactive Against a Polymorphic Determinant of HLA-DR Expressed on B Cells
P2860
Q28270899-141455B2-FDF7-45F3-AFE6-554013792BC1Q30353154-A7879763-EBDB-4A3E-8117-105ACFF95E94Q34589909-439F55E3-A1ED-4BA2-AC82-C285E8E359FEQ35684872-F9ACDE8B-03CA-45CD-B674-DF18A5F093BDQ35849245-B1999319-CA54-4887-87E7-F141CDE116B0Q36108610-BE7EAC28-3312-483B-BD10-8CC0E8E5BB65Q37220742-891FBFE9-8B56-477E-BD87-5B94C56B5F9EQ37667386-EB7DBBA6-607C-4653-B2BD-A974C7B6C7BEQ37852003-3FA93309-F392-4EC4-9C95-99A6B9E809F0Q38090680-74242C1D-6AC5-4E7A-B9FE-A07483AE1757Q38899715-0DA310BE-6953-4DD3-BC30-DE652AFC17C5Q40135352-210F04D9-9EAC-454A-B193-638C05572D87Q40146896-12F24D59-1AD1-4745-8527-B553996AA89CQ40162436-C5A403D4-CF74-4424-978F-FD21CC024644Q40374914-8F3F9377-E53E-4CD1-9E4A-FC526CC26B38Q40375510-7A39E263-7D72-4D16-B5B9-CC4EE381A0D0Q40558843-EDB3C774-C09E-4E67-9E21-5720B1006AD8Q44497849-225C2BCA-365E-4543-8D3B-DC7B0BE9D025Q44872972-29A5EB95-2081-43BD-B1C6-00926B03DEA8Q57373163-81CD632F-555E-4BF4-B7E8-B3103932B4CC
P2860
Humanization and characterization of the anti-HLA-DR antibody 1D10.
description
2001 nî lūn-bûn
@nan
2001年の論文
@ja
2001年学术文章
@wuu
2001年学术文章
@zh
2001年学术文章
@zh-cn
2001年学术文章
@zh-hans
2001年学术文章
@zh-my
2001年学术文章
@zh-sg
2001年學術文章
@yue
2001年學術文章
@zh-hant
name
Humanization and characterization of the anti-HLA-DR antibody 1D10.
@en
Humanization and characterization of the anti-HLA-DR antibody 1D10.
@nl
type
label
Humanization and characterization of the anti-HLA-DR antibody 1D10.
@en
Humanization and characterization of the anti-HLA-DR antibody 1D10.
@nl
prefLabel
Humanization and characterization of the anti-HLA-DR antibody 1D10.
@en
Humanization and characterization of the anti-HLA-DR antibody 1D10.
@nl
P2093
P2860
P356
P1476
Humanization and characterization of the anti-HLA-DR antibody 1D10
@en
P2093
B H Jorgensen
G J Weiner
S A Kostelny
P2860
P304
P356
10.1002/IJC.1366
P50
P577
2001-08-01T00:00:00Z